Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Recommendation of “Moderate Buy” by Brokerages

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has earned a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $13.57.

IRWD has been the topic of several research analyst reports. Capital One Financial cut Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $12.00 to $4.00 in a research note on Thursday, August 8th. StockNews.com raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, July 16th. Leerink Partnrs raised Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. Wells Fargo & Company lowered their price target on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, August 9th. Finally, Leerink Partners started coverage on Ironwood Pharmaceuticals in a research note on Monday, September 9th. They issued a “market perform” rating and a $5.00 price target for the company.

Insiders Place Their Bets

In other Ironwood Pharmaceuticals news, insider Minardo John sold 9,910 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $4.27, for a total transaction of $42,315.70. Following the completion of the sale, the insider now owns 284,661 shares of the company’s stock, valued at $1,215,502.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 12.90% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Ironwood Pharmaceuticals by 21.8% during the first quarter. Vanguard Group Inc. now owns 19,521,366 shares of the biotechnology company’s stock worth $170,031,000 after purchasing an additional 3,487,821 shares during the last quarter. Pacer Advisors Inc. raised its position in shares of Ironwood Pharmaceuticals by 23.6% during the second quarter. Pacer Advisors Inc. now owns 8,907,639 shares of the biotechnology company’s stock worth $58,078,000 after purchasing an additional 1,701,452 shares during the period. Renaissance Technologies LLC raised its position in shares of Ironwood Pharmaceuticals by 20.7% during the second quarter. Renaissance Technologies LLC now owns 8,571,898 shares of the biotechnology company’s stock worth $55,889,000 after purchasing an additional 1,472,097 shares during the period. Armistice Capital LLC raised its position in Ironwood Pharmaceuticals by 44.4% in the 2nd quarter. Armistice Capital LLC now owns 7,800,000 shares of the biotechnology company’s stock valued at $50,856,000 after buying an additional 2,400,000 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its position in Ironwood Pharmaceuticals by 40.8% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 4,235,580 shares of the biotechnology company’s stock valued at $36,892,000 after buying an additional 1,226,377 shares during the last quarter.

Ironwood Pharmaceuticals Price Performance

NASDAQ:IRWD opened at $4.30 on Monday. Ironwood Pharmaceuticals has a fifty-two week low of $3.79 and a fifty-two week high of $15.70. The stock’s 50-day moving average is $5.34 and its two-hundred day moving average is $6.60. The stock has a market cap of $673.07 million, a PE ratio of -0.63 and a beta of 0.49.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.